China’s Pharmaceutical Regulatory Landscape: Key Developments in 2024–2025
China’s pharmaceutical sector has been undergoing significant transformations in the past year, with sweeping reforms affecting drug reimbursement, approval processes, market access pathways, and the oversight of pharmaceutical representatives. Together, these policy shifts aim to enhance access to high-quality treatments, increase efficiency... Read More